The antibiotic removal device manufactured by Marion Laboratories (Kansas City, Mo.) is intended for treatment, before culture, of blood specimens from hospital patients being treated with antibiotics. Measurement of 13 antibiotics showed that the antibiotic removal device removed amikacin, ampicillin, carbenicillin, cefazolin, cephalothin, chloramphenicol, gentamicin, nafcillin, tetracycline, tobramycin, and vancomycin and reduced cefoxitin and ticarcillin to extremely low levels. Three combinations of antibiotics were similarly removed or reduced. Five species of anaerobic bacteria, one yeast species, and six species of facultative or aerobic bacteria were used to challenge the possibility that the antibiotic removal device would trap or inhibit microorganisms. All were recovered from the device in the same numbers as were inoculated.
It is theoretically possible for antibiotics given to a hospital patient for prophylaxis or treatment to inhibit the growth of bacteria in blood cultures made for diagnosis or therapy management. It was shown early in the antibiotics era that such inhibition could be decreased by adding concentrated penicillinase to blood cultures (1) , leading to the current common practive of adding penicillinase to blood cultures from persons who have received a penicillin. The heparinoid anticoagulant sodium polyanetholesulfonate is widely used in blood cultures partly because it inactivates several aminoglycoside and polymyxin class antibiotics (3, 5) . The report that this inactivation by sodium polyanetholesulfonate may be culture medium dependent (6) could mean that sodium polyanetholesulfonate effectiveness is diminished in some blood culture formulae. The only recourse for doing blood cultures for patients in the course of antibiotic therapy, beyond these systems, has been reliance upon the dilution effect of the 5:1, 10:1, or 20:1 ratio between culture broth and blood inoculum.
Marion Laboratories (Kansas City, Mo.) has developed a device to be used for removing antibiotics from blood specimens before inoculating them to broth. The device consists of a 50-ml serum bottle containing treated plastic resins to which a solution of 0.025% sodium polyanetholesulfonate in saline has been added. It is fitted with a rubber stopper with septum and has a filter in the neck to retain resin fines when the treated blood is removed. From 5 to 10 ml of blood is aseptically injected through the septum, and the bottle is tumbled end-over-end for 15 min on a simple mechanical tumbler at prescribed force and speed. The blood sample is then withdrawn by syringe and inoculated into any blood culture broth.
The numbers of microorganisms circulating in septicemia may be small. Our unpublished records show that more than half of blood specimens from patients with confirmed septicemia have a count of less than 1 colony-forming unit per ml.
In some applications resins similar to those in this antibiotic removal device (ARD) are used as microbial trapping filters. Evaluation of this device requires then that it be shown both to remove antibiotics and not to inhibit microorganisms in, or retain them from, blood specimens. We report the results of experiments addressed to both of these questions. Trimethoprim and sulfamethoxazole could not be measured exactly but were estimated on Mueller-Hinton agar or on Mueller-Hinton agar containing 5% lysed sheep blood, respectively.
MATERIALS AND METHODS
Assay designs. The antibiotics in Table 1 were used individually at about the expected clinical concentration to challenge the ARD. In addition, the ARD was challenged with elevated concentrations of ampicillin, chloramphenicol, gentamicin, tobramycin, and ticarcillin.
The system was also challenged with the following antimicrobial mixtures: trimethoprim + sulfamethoxazole, cefazolin + tobramycin, ticarcillin + tobramycin, 
RESULTS
Single antibiotics challenge. Precision of these assay systems was +10% for gentamicin and tobramycin, ±15% for amikacin, and ±15% of control for others. The detection limit, defined as the lowest concentration at which even slight activity is consistently detected, was about onehalf the lowest concentration on the standard curve for amikacin, chloramphenicol, tobramycin, and tetracycline and one-twentieth to onetenth the lowest standard concentration for all others. Table 1 for cefazolin, ticarcillin, and vancomycin demonstrates that the ARD system was not compromised by combining antibiotics. Trimethoprim and sulfamethoxazole each interfered in the assay for the other, so a precise value in the assay system for their removal could not be assigned. However, it is clear that there was sufficient activity of each before ARD treatment to permit the conclusion that ARD treatment removes both.
Time required for removal. Table 3 growth in the bottle but without countable colonies.
DISCUSSION
The antimicrobial agents used for challenge in these studies represent those most used for treatment of septicemia and included one or more representatives of each of the major antibiotics classes, as well as the combination trimethoprim-sulfamethoxazole. The device is described for use in blood cultures only from patients receiving antimicrobial treatment for serious infections. The ARD system either removes each of the tested drugs to a level below the limit of its assay system (apparent zero) or reduces it to a very low level. For example, if the reduction of 171 ,ug of cefazolin per ml by at least 99% in our experiment is extrapolated to an expected clinical concentration of about 50 ,ug/ ml, that clinical concentration would be reduced to 0.05 ,ug/mI or less. The minimum inhibitory concentration of cefazolin against most gramnegative bacteria is greater than 1 ,ug/ml, and that against gram-positive bacteria is about 0.5 ,ug/mI and only very rarely as low as 0.05 ,ug/ml. This ought to mean that 0.05 ug of cefazolin per ml, reduced by dilution to 0.005,ug/ml in most blood culture systems, is not sufficient to inhibit in vitro growth of most bacteria surviving in the blood of a treated person. Similar reasoning could be applied to vancomycin and ticarcillin, the other antibiotics found to have trace residual activity after ARD treatment.
The removal device is effective against two penicillins, two new semisynthetic penicillins, three aminoglycosides, one tetracycline, and sulfamethoxazole. The mechanisms by which this device removes antimicrobial activity are probably nonpartitional absorption or cationic exchange by the resins and inactivation by sodium polyanetholesulfonate. Although the ARD was not challenged with every antibiotic, we are willing to speculate, from these results and the nature of the ARD function, that it very likely will be found effective against other members of the antimicrobial "families" tested. Of course many of the antibacterial agents not tested are not ordinarily used for treating systemic infections.
We have not measured the capacity of this device to remove immune globulin, complement, or bacterial metabolic products, such as polysaccharide or lipid. Such removal, if it occurs, might be either irrelevant to or possibly an additional advantage in bacterial growth. Finally, capacity of this device to remove antifungal drugs as well as antibacterial ones remains to be determined.
The device did not inhibit or kil bacteria used for challenge. Efforts were made to select for challenge numbers of each test organism low enough to simulate the numbers expected in bacteremia yet high enough to permit the counting of colonies. 21 were negative with and without ARD treatment, 4 were positive both with and without ARD treatment, and 22 were positive with ARD treatment but negative without ARD treatment. Wallis and colleagues (7) and Melnick (4) report similar results.
In conclusion, it seems clear that the ARD does remove antibiotics and does not interfere with bacterial growth from ARD-treated blood specimens. Continued effectiveness of this device will require that it be challenged with new antimicrobial agents as these are developed. 
